Genmab — April 2017
-
-
-
lugter det her ikke lidt af, at der kommer en godkendelse i dag?
-
Der må ske et eller andet som vi "dødelige" ikke har indsigt i...
-
Speculation, but from my point of view, Genmab suffered from a short attack on the back of the discontinued phase 2 studies. Last couple of weeks we have seen relatively huge dumps being unloaded by AB, every time the stock showed a little strength. Aggressively selling into the market like that is often a sign of protecting ones short position, by creating doubt and frustration. I think these positions are being closed at the moment.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind